Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral estramustine phosphate (Estracyt): a broad phase II study.

J Halpern, R Catane

    Journal of Medicine
    |January 1, 1984
    PubMed
    Summary

    Estramustine phosphate (Estracyt) showed limited efficacy in advanced cancers, with one partial response in hormone-resistant prostate cancer. Minor responses were observed in prostate, colorectal, and melanoma cancers, with manageable toxicity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Increased retention of tau PET ligand [<sup>18</sup>F]-AV1451 in Alzheimer's Disease Psychosis.

    Translational psychiatry·2022
    Same author

    A price tag on clinical empathy? Factors influencing its cost-effectiveness.

    Journal of the Royal Society of Medicine·2020
    Same author

    Oral delivery of Hyperimmune bovine serum antibodies against CS6-expressing enterotoxigenic <i>Escherichia coli</i> as a prophylactic against diarrhea.

    Gut microbes·2020
    Same author

    Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same author

    Ethical, moral, and theological insights into advances in male pediatric and adolescent fertility preservation.

    Andrology·2017
    Same author

    Trainee perspectives on postdoctoral recruitment in clinical neuropsychology: reflections on commentaries by Bodin and Grote (2016) and Nelson et al. (2016).

    The Clinical neuropsychologist·2017

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Estramustine phosphate (Estracyt) is an antineoplastic agent.
    • Investigated for efficacy in advanced malignancies.

    Observation:

    • Thirty-five patients with advanced cancers received estramustine phosphate at doses of 420-700 mg daily.
    • Treatment outcomes and toxicity profiles were monitored.

    Findings:

    • One partial response was observed in a patient with hormone-resistant prostate cancer.
    • Four minor responses were noted: one in hormone-resistant prostate cancer, two in metastatic colorectal cancer, and one in malignant melanoma.
    • Common toxicities included nausea (25%), water retention (11.5%), and mild alkaline phosphatase elevation (6%).

    Implications:

    • Estramustine phosphate demonstrates limited activity in heavily pre-treated advanced cancers.
    • The drug is generally well-tolerated, with manageable side effects.
    • Further research may explore its role in specific refractory cancer types.

    Related Experiment Videos